Free shipping on all orders over $ 500

 About 7 results found for searched term "MurA-IN-4" (0.119 seconds)

Cat.No.  Name Target
M41058 MurA-IN-4 Antibiotic
MurA-IN-4 has antibacterial activity and is a MurA inhibitor that inhibits bacterial cell wall synthesis.
M1761 Vemurafenib (PLX4032) Raf
RG7204; RO5185426
Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy.
M10886 Samuraciclib hydrochloride CDK
Samuraciclib (ICEC0942, CT7001) is a novel oral CDK7 inhibitor with an IC50 of 40 nM. It has IC50 values for other CDK proteins such as CDK1, CDK2, CDK5 and CDK9 as 45, 15, 230 and 30 times higher than that of CDK7 IC50, respectively. ICEC0942 (CT7001) promotes cell cycle blocking and apoptosis.
M18517 Ishophloroglucin A Others
IPA
Ishophloroglucin A, isolated from Ishige okamurae, is a potent PTP1B inhibitor with IC50 of 0.43 μM, inhibits adipogenesis in 3T3-L1 adipocytes.
M21513 Vemurafenib-d7 Raf
PLX4032-d7; RG7204-d7; RO5185426-d7
Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy.
M21520 Vemurafenib-d5 Raf
Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively.
M28894 Samuraciclib CDK
CT7001; ICEC0942
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.